4//SEC Filing
Horizon Pharma plc 4
Accession 0001209191-14-059111
CIK 0001492426operating
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 8:11 PM ET
Size
27.0 KB
Accession
0001209191-14-059111
Insider Transaction Report
Form 4
DE VAERE ROBERT J
EVP and CFO
Transactions
- Award
Stock Option (Right to Buy)
2014-09-19+42,295→ 42,295 totalExercise: $12.94Exp: 2020-06-05→ Ordinary Shares (42,295 underlying) - Award
Stock Option (Right to Buy)
2014-09-19+53,621→ 53,621 totalExercise: $4.96Exp: 2021-12-07→ Ordinary Shares (53,621 underlying) - Award
Ordinary Shares
2014-09-19+94,290→ 94,290 total - Award
Stock Option (Right to Buy)
2014-09-19+47,654→ 47,654 totalExercise: $5.20Exp: 2020-02-02→ Ordinary Shares (47,654 underlying) - Award
Restricted Stock Units
2014-09-19+33,750→ 33,750 total→ Ordinary Shares (33,750 underlying) - Award
Stock Option (Right to Buy)
2014-09-19+51,000→ 51,000 totalExercise: $2.40Exp: 2023-01-01→ Ordinary Shares (51,000 underlying) - Award
Stock Option (Right to Buy)
2014-09-19+46,335→ 46,335 totalExercise: $10.43Exp: 2018-10-05→ Ordinary Shares (46,335 underlying) - Award
Restricted Stock Units
2014-09-19+16,416→ 16,416 total→ Ordinary Shares (16,416 underlying) - Award
Stock Option (Right to Buy)
2014-09-19+70,000→ 70,000 totalExercise: $7.61Exp: 2024-01-01→ Ordinary Shares (70,000 underlying) - Award
Restricted Stock Units
2014-09-19+62,000→ 62,000 total→ Ordinary Shares (62,000 underlying)
Footnotes (7)
- [F1]Acquisition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc., Vidara Therapeutics Holdings LLC, the Issuer (formerly known as Vidara Therapeutics International Ltd.), Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of Horizon Pharma, Inc. are being canceled and automatically converted into securities of the Issuer. The Reporting Person's disposition of securities of Horizon Pharma, Inc. in the Merger will be reported on a separate Form 4.
- [F2]The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.
- [F3]In connection with the Merger, the stock option originally granted by Horizon Pharma, Inc. has been converted into an option to purchase the same number of ordinary shares of the Issuer at the same exercise price and on substantially the same terms.
- [F4]The stock option vests in 48 equal monthly installments following the grant date of 1/2/2013. The option will become fully vested and immediately exercisable on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
- [F5]Each restricted stock unit represented a contingent right to receive one share of Horizon Pharma, Inc. common stock. Each restricted stock unit has been converted into a contingent right to receive one ordinary share of the Issuer.
- [F6]The restricted stock units vest in four equal annual installments. The units will become fully vested on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
- [F7]The stock option vests in 48 equal monthly installments following the grant date of 1/2/2014. The option will become fully vested and immediately exercisable on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
Documents
Issuer
Horizon Pharma plc
CIK 0001492426
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001492426
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 8:11 PM ET
- Size
- 27.0 KB